HROW Quote, Financials, Valuation and Earnings

iBio has a net margin of -8.57% compared to Harrow's net margin of -4444.57%. Harrow's return on equity of -51.9% beat iBio's return on equity of -148.3%.

Harrow has a consensus price target of --, signalling upside risk potential of 75.98%. On the other hand iBio has an analysts' consensus of -- which suggests that it could grow by 52.54%. Given that Harrow has higher upside potential than iBio, analysts believe Harrow is more attractive than iBio.

Harrow has a beta of 0.693, which suggesting that the stock is 30.669% less volatile than S&P 500. In comparison iBio has a beta of -3.237, suggesting its less volatile than the S&P 500 by 423.713%.

Harrow has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harrow pays -- of its earnings as a dividend. iBio pays out -- of its earnings as a dividend.

Harrow quarterly revenues are $49.3M, which are larger than iBio quarterly revenues of $175K. Harrow's net income of -$4.2M is lower than iBio's net income of -$4M. Notably, Harrow's price-to-earnings ratio is -- while iBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harrow is 7.15x versus -- for iBio. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -8.57% compared to Harrow's net margin of -49.65%. Harrow's return on equity of -51.9% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Harrow has a consensus price target of --, signalling upside risk potential of 75.98%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 620.92%. Given that NovaBay Pharmaceuticals has higher upside potential than Harrow, analysts believe NovaBay Pharmaceuticals is more attractive than Harrow.

Harrow has a beta of 0.693, which suggesting that the stock is 30.669% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Harrow has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harrow pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Harrow quarterly revenues are $49.3M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Harrow's net income of -$4.2M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Harrow's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harrow is 7.15x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -8.57% compared to Harrow's net margin of -2357.27%. Harrow's return on equity of -51.9% beat Palatin Technologies's return on equity of --.

Harrow has a consensus price target of --, signalling upside risk potential of 75.98%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1652.58%. Given that Palatin Technologies has higher upside potential than Harrow, analysts believe Palatin Technologies is more attractive than Harrow.

Harrow has a beta of 0.693, which suggesting that the stock is 30.669% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

Harrow has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harrow pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Harrow quarterly revenues are $49.3M, which are larger than Palatin Technologies quarterly revenues of $350K. Harrow's net income of -$4.2M is higher than Palatin Technologies's net income of -$7.8M. Notably, Harrow's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harrow is 7.15x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -8.57% compared to Harrow's net margin of --. Harrow's return on equity of -51.9% beat Theriva Biologics's return on equity of --.

Harrow has a consensus price target of --, signalling upside risk potential of 75.98%. On the other hand Theriva Biologics has an analysts' consensus of $100.00 which suggests that it could grow by 6861.54%. Given that Theriva Biologics has higher upside potential than Harrow, analysts believe Theriva Biologics is more attractive than Harrow.

Harrow has a beta of 0.693, which suggesting that the stock is 30.669% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.329, suggesting its more volatile than the S&P 500 by 32.874%.

Harrow has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harrow pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Harrow quarterly revenues are $49.3M, which are larger than Theriva Biologics quarterly revenues of --. Harrow's net income of -$4.2M is higher than Theriva Biologics's net income of -$7.7M. Notably, Harrow's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harrow is 7.15x versus 0.90x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.